Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).

Two Claudin18.2 targeting ADCs from CSPC and Kelun involved in billion dollar deals

SOTIO Biotech

13/8/2022 | 3 minuty čtení

Vytisknout
Kopírovat odkaz

ACQUISITIONS

AstraZeneca to acquire single-asset TeneoTwo, a spinout from TeneoBio, for $100 million up front

AstraZeneca is adding a clinical bispecific T cell engager to its pipeline in a deal that brings the total sale price of TeneoBio and associated assets to $1.4 billion across three upfront payments. Amgen acquired TeneoBio last year for $900 million upfront, AbbVie had previously purchased another single-asset affiliate, TeneoOne, for $400 million upfront. TeneoTwo was among three asset-focused start-ups created to house programs not included in the Amgen takeout. AstraZeneca will now advance TeneoTwo’s TNB-486, which targets CD3 and CD19 to treat hematological malignancies. The pharma has reached Phase 1 to treat relapsed or refractory B cell NHL and will aim to develop TNB-486 further in diffuse large B cell lymphoma and follicular lymphoma. AstraZeneca said it intends to test TNB-486 in combinations, including pairings with CD20-targeting therapeutics, that could lead to a new standard of care in B cell malignancies. TBio’s shareholders are eligible for $805 million in R&D-related milestones tied to TNB-486, as well as $360 million in commercial milestones.

PARTNERING

ADC Therapeutics out-licenses European rights to SOBI for $55 million upfront

A deal with ADC Therapeutics will give Swedish Orphan Biovitrum (SOBI) rights to commercialize Zynlonta loncastuximab tesirine-lpyl in the EU. It is under review in that jurisdiction, with a decision due by 1Q23. ADC Therapeutics will receive $55 million upfront and is eligible for $50 million on first EC approval and about $330 million in additional regulatory and sales milestones, plus royalties up to the mid-twenties. SOBI’s territories include all those outside the US, China, Singapore and Japan. The companies will share the cost of select global Zynlonta clinical trials. In April 2021, FDA approved Zynlonta, a CD19-targeted ADC, to treat relapsed or refractory large B cell lymphoma after two or more lines of systemic therapy.

Exelixis and Poland-based Ryvu will develop targeted therapies using STING agonists

Exelixis and Ryvu Therapeutics entered into an exclusive license agreement focused on the development of novel targeted therapies utilizing Ryvu’s STING (STimulator of INterferon Genes) technology. The agreement is focused on Ryvu’s proprietary small molecule STING agonists and STING biology know-how. Exelixis will pay Ryvu an upfront fee of $3 million in exchange for certain rights to Ryvu’s STING agonist small molecules, which Exelixis will seek to incorporate into targeted therapies such as ADCs. Exelixis will lead all research activities and, upon selection of each development candidate, will be responsible for all development and commercialization activities.

Elevation Oncology paying $27 million upfront for  ADC targeting Claudin18.2 from CSPC

Elevation Oncology will gain exclusive worldwide rights outside of China to SYSA1801 (newly EO-3021) from CSPC Megalith Biopharmaceutical with the intention of launching a phase 1 US trial in 2023 for the oncology asset. CSPC is a subsidiary of CSPC Pharmaceutical Group in China. FDA has already okayed an IND application for EO-3021, clearing the candidate to be tested in humans in the US. EO-3021 is a differentiated ADC targeting Claudin18.2 and is currently being investigated by CSPC in a Phase 1 dose-escalation clinical trial in China. CSPC also has the potential to receive up to $148 million in milestone payments and up to $1 billion in commercial milestone payments plus royalties on net sales. Elevation’s one-time $27 million upfront payment to CSPC will be paid primarily using a new $50 loan from K2 HealthVentures, an alternative investment firm for life sciences and healthcare companies.

Merck and Kelun entered a second ADC-targeting deal now for $35 million upfront

For the second time this year, Merck & Co. and Sichuan Kelun Pharmaceutical have aligned for a development deal, this time around an ADC against an undisclosed target. Kelun will receive $35 million up front and is eligible for $901 million in milestones, plus royalties. The parties will collaborate on early clinical development, and Merck has a global license. Kelun is active in the US through its subsidiary Klus Pharma. Its pipeline include multiple compounds, but the early clinical ADC is only SKB315, which is targeting Claudin18.2. The latest partnership follows Merck’s exercise of an option to license TROP2-targeting ADC SKB-264, which is in Phase 3 testing to treat triple-negative breast cancer and Phase 2 for non-small cell lung cancer and other solid tumors.

Overview of transactions in oncology (values in m$)

Source

Partner

Product

Stage

Rights

Value

UF

MS

ADC Therapeutics

Swedish Orphan Biovitrum

License to commercialize Zynlonta, the CD19-targeted ADC approved for B cell lymphoma

Market

EU

430

50

380

Orion Corp.

Merck & Co.

License to ODM-208, a small molecule CYP11A1 blocker tested in prostate cancer

Ph 2

WW

NA

290

NA

TeneoTwo

AZ

Acquisition of single product company with TNB-486, a bispecific T cell engager targeting CD3 and CD19 against NHL

Ph 1

NV

1 265

100

1 165

CSPC Pharma

Elevation Oncology

License to SYSA1801, an CLDN18.2 targeting ADC tested in solid tumor indications

Ph 1

Ex-CN,      HK,TW,      MC

1 175

27

1 148

Kelun Pharma

Merck & Co.

License to undisclosed early clinical ADC against cancer, likely the SKB315 targeting CLDN18.2

Ph 1

WW

936

35

901

Palleon Pharma

Henlius Biotech

License to two bifunctional sialidase programs from EAGLE platform against cancer

Precl

CN,HK, TW,MC

 NA

NA

197

Tarus Therapeutics

Portage Biotech

Acquisition of company with ADORA2A and ADORA2B inhibitors against solid tumors, incl. TT-10, TT-4, TT-53 and TT-3

Precl

NV

53

21

32

Skyhawk Therapeutics

Sanofi

License to small molecules that modulate RNA splicing via SkySTAR platform against cancer

Res

WW

2 054

54

2 000

Ryvu Therapeutics

Exelixis

License to small molecule STING agonists to be incorporated into therapies like ADCs for cancer

Res

WW

NA

3

NA

NASDAQ Initial Public Offerings (IPOs) in oncology

Company

Ticker

Lead Product

Technology

Stage

Amount m$

Price $

MAIA Biotechnology

MAIA

Thio

Small molecule telomere targeting agent for the treatment of NSCLC in combination with cemiplimab

Phase 2

10.0

5

Sdílet na sociálních sítích

Sdílet na sociálních sítích

Vytisknout

Kopírovat odkaz